Wedica 100 mg contains Trelagliptin, a once-weekly oral medication used for the management of type 2 diabetes mellitus (T2DM). Trelagliptin belongs to the class of dipeptidyl peptidase-4 (DPP-4) inhibitors, which help regulate blood glucose levels by enhancing the body’s own incretin system. It is designed for patients who require better glycemic control and prefer a convenient, low-frequency dosing regimen.

Trelagliptin works by inhibiting the DPP-4 enzyme, which normally breaks down incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide). These hormones stimulate insulin secretion in response to meals and suppress glucagon release, leading to improved postprandial and fasting glucose control. By prolonging incretin activity, Wedica helps normalize blood sugar levels in patients with type 2 diabetes without causing significant hypoglycemia.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Wedica 100 mg is indicated for:

• Management of type 2 diabetes mellitus in adults, either as monotherapy or in combination with other oral antidiabetic agents such as metformin, sulfonylureas, or SGLT2 inhibitors.

• Patients who require additional glycemic control despite lifestyle interventions, including diet and exercise.

Therapeutic Class

• Antidiabetic Agent

• DPP-4 Inhibitor

Pharmacology

Trelagliptin selectively inhibits the DPP-4 enzyme, preventing the degradation of incretin hormones. This results in:

• Increased glucose-dependent insulin secretion from pancreatic beta cells.

• Suppression of inappropriate glucagon secretion from pancreatic alpha cells.

• Reduction in postprandial and fasting plasma glucose levels.

Unlike some other antidiabetic medications, Trelagliptin has a low risk of hypoglycemia because its insulin-stimulating effects are glucose-dependent. Its long half-life allows for once-weekly oral dosing, enhancing patient adherence and convenience.

Dosage and Administration

• The recommended dose of Wedica is 100 mg orally, once weekly, with or without food.

• The tablet should be swallowed whole with water.

• Dose adjustments may be necessary in patients with moderate to severe renal impairment.

• Regular monitoring of blood glucose, HbA1c, and renal function is recommended to assess therapeutic efficacy and safety.

Key Benefits

• Once-weekly dosing improves patient adherence and convenience.

• Effective in reducing fasting and postprandial blood glucose.

• Low risk of hypoglycemia when used as monotherapy.

• Can be safely combined with other antidiabetic agents for comprehensive glycemic control.

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Precautions and Warnings

• Use with caution in patients with moderate to severe renal impairment.

• Monitor for signs of pancreatitis, as DPP-4 inhibitors may rarely be associated with pancreatic inflammation.

• Not recommended in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.

• Pregnancy and breastfeeding use should be discussed with a physician.

Adverse Effects

Common adverse effects may include headache, nasopharyngitis, upper respiratory tract infection, and mild gastrointestinal discomfort. Severe adverse events are rare but may include hypersensitivity reactions or pancreatitis.

Storage

Store below 30°C in a dry place, protected from light and moisture. Keep out of reach of children.

Wedica 100 mg offers a convenient and effective oral treatment for type 2 diabetes, helping patients achieve better glycemic control with minimal risk of hypoglycemia and improved treatment adherence.